The Wall Street Journal: Pfizer working on freeze-dried version of COVID-19 vaccine that doesn’t need ultracold storage

Pfizer Inc. and partner BioNTech SE plan to begin soon testing a freeze-dried version of its COVID-19 vaccine, which if proven to work safely could ease storage and handling of the shots in rural U.S. areas and low-income countries. Read More...

Pfizer Inc. PFE, -1.39% and partner BioNTech SE BNTX, +8.89% plan to begin soon testing a freeze-dried version of its COVID-19 vaccine, which if proven to work safely could ease storage and handling of the shots in rural U.S. areas and low-income countries.

In April, Pfizer is set to start a clinical trial evaluating a so-called lyophilized formulation in adults 18 to 55 years old in the U.S., according to a government database, clinicaltrials.gov, and confirmed by the company.